Wellington Management Group LLP Sells 29,501 Shares of Inhibrx, Inc. (NASDAQ:INBX)

Wellington Management Group LLP lowered its position in Inhibrx, Inc. (NASDAQ:INBX) by 16.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 145,398 shares of the company’s stock after selling 29,501 shares during the period. Wellington Management Group LLP owned 0.31% of Inhibrx worth $5,525,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Vestal Point Capital LP acquired a new stake in Inhibrx during the 4th quarter valued at $58,140,000. RA Capital Management L.P. increased its stake in shares of Inhibrx by 22.6% in the third quarter. RA Capital Management L.P. now owns 4,724,207 shares of the company’s stock valued at $86,689,000 after buying an additional 870,340 shares in the last quarter. PFM Health Sciences LP raised its holdings in shares of Inhibrx by 86.4% in the fourth quarter. PFM Health Sciences LP now owns 537,964 shares of the company’s stock valued at $20,443,000 after buying an additional 249,347 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Inhibrx during the 4th quarter worth about $894,000. Finally, Vanguard Group Inc. grew its holdings in Inhibrx by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,789,811 shares of the company’s stock worth $32,843,000 after acquiring an additional 18,271 shares during the last quarter. 82.46% of the stock is owned by institutional investors and hedge funds.

Inhibrx Stock Up 0.8 %

Shares of NASDAQ INBX opened at $14.17 on Friday. Inhibrx, Inc. has a 1-year low of $13.67 and a 1-year high of $18.95. The company has a 50-day moving average of $26.47 and a two-hundred day moving average of $32.29.

Insider Activity at Inhibrx

In other Inhibrx news, insider Brendan P. Eckelman sold 300,000 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $34.30, for a total transaction of $10,290,000.00. Following the transaction, the insider now owns 1,735,553 shares of the company’s stock, valued at approximately $59,529,467.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Inhibrx news, insider Brendan P. Eckelman sold 300,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.30, for a total transaction of $10,290,000.00. Following the completion of the sale, the insider now directly owns 1,735,553 shares of the company’s stock, valued at approximately $59,529,467.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jon Faiz Kayyem bought 57,549 shares of Inhibrx stock in a transaction dated Wednesday, June 5th. The stock was acquired at an average cost of $17.32 per share, for a total transaction of $996,748.68. Following the purchase, the director now directly owns 1,150,410 shares in the company, valued at approximately $19,925,101.20. The disclosure for this purchase can be found here. 22.20% of the stock is currently owned by company insiders.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.